6259-86-5

Upstream product

• 22511-06-4 3,4-dimethoxyphenylpropiolic acid 
• 816462-34-7 3,4-dimethoxyphenylpropioloyl chloride 
• 58095-76-4 (E)-3-(benzo[d][1,3]dioxol-5-yl)prop-2-en-1-ol 

Downstream Products

• 31888-76-3 1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-6,7-methylenedioxynaphthalene-2-carboxylic acid lactone 
• 31786-43-3 1-(3,4-dimethoxyphenyl)-3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxynaphthalene-2-carboxylic acid lactone 

Relevant academic research and scientific papers

Studies on disease-modifying antirheumatic drugs. III. Bone resorption inhibitory effects of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and related compounds

In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the potent bone resorption inhibitors justicidins, was performed and various naphthalene lactones, quinoline lactones and quinoline derivatives bearing an azole moiety at the side chain were prepared. Their inhibitory effects on bone resorption were evaluated by Raisz's method, and several compounds, including ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1- ylmethyl)quinoline-3-arboxylate (6c, TAK-603), were found to have activities comparable with or superior to the justicidins. The 4-(3-isopropoxy-4- methoxy)phenyl derivative (6d), in particular, displayed a marked increase in potency. TAK-603 and compound 6d were very effective in preventing osteoclast formation and bone resorption by mature osteoelasts. Further, TAK-603 was shown to be effective in preventing bone loss in ovariectomized mice.